Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Sela

Showing results (21-30 of 41) with videos related to

Pageof 5
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|February 17, 2009
Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosisTsipi Ben-Kasus, Bilha Schechter, Sara Lavi, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 17, 2006
A 50-kDa ERK-like protein is up-regulated by a dual altered peptide ligand that suppresses myasthenia gravis-associated responsesHava Ben-David, Badiga Venkata Aruna, Rony Seger, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 1, 2013
Aptamer to ErbB-2/HER2 enhances degradation of the target and inhibits tumorigenic growthGeorg Mahlknecht, Ruth Maron, Maicol Mancini, et al.
Journal of Neuroimmunology|July 4, 2012
Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitisRina Aharoni, Ravit Saada, Raya Eilam, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 5, 2013
Inhibition of pancreatic carcinoma by homo- and heterocombinations of antibodies against EGF-receptor and its kin HER2/ErbB-2Ruth Maron, Bilha Schechter, Maicol Mancini, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 21, 2005
The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis miceRina Aharoni, Raya Eilam, Hagit Domev, et al.
Glia|February 10, 2018
Astrocyte disruption of neurovascular communication is linked to cortical damage in an animal model of multiple sclerosisRaya Eilam, Menahem Segal, Rafael Malach, et al.
Human Immunology|June 29, 2004
Immunomodulation by a dual altered peptide ligand of autoreactive responses to the acetylcholine receptor of peripheral blood lymphocytes of patients with myasthenia gravisMolly Dayan, Zev Sthoeger, Alex Neiman, et al.
Translational Oncology|October 4, 2011
Simultaneous Inhibition of Estrogen Receptor and the HER2 Pathway in Breast Cancer: Effects of HER2 AbundanceAnna Emde, Georg Mahlknecht, Kerstin Maslak, et al.
Experimental Neurology|November 17, 2012
Magnetic resonance imaging characterization of different experimental autoimmune encephalomyelitis models and the therapeutic effect of glatiramer acetateRina Aharoni, Efrat Sasson, Tamar Blumenfeld-Katzir, et al.
Pageof 5

Showing results (21-30 of 41) with videos related to

Sort By:
Pageof 5
Proceedings of the National Academy of Sciences of the United States of America|February 17, 2009
Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosisTsipi Ben-Kasus, Bilha Schechter, Sara Lavi, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 17, 2006
A 50-kDa ERK-like protein is up-regulated by a dual altered peptide ligand that suppresses myasthenia gravis-associated responsesHava Ben-David, Badiga Venkata Aruna, Rony Seger, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 1, 2013
Aptamer to ErbB-2/HER2 enhances degradation of the target and inhibits tumorigenic growthGeorg Mahlknecht, Ruth Maron, Maicol Mancini, et al.
Journal of Neuroimmunology|July 4, 2012
Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitisRina Aharoni, Ravit Saada, Raya Eilam, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 5, 2013
Inhibition of pancreatic carcinoma by homo- and heterocombinations of antibodies against EGF-receptor and its kin HER2/ErbB-2Ruth Maron, Bilha Schechter, Maicol Mancini, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 21, 2005
The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis miceRina Aharoni, Raya Eilam, Hagit Domev, et al.
Glia|February 10, 2018
Astrocyte disruption of neurovascular communication is linked to cortical damage in an animal model of multiple sclerosisRaya Eilam, Menahem Segal, Rafael Malach, et al.
Human Immunology|June 29, 2004
Immunomodulation by a dual altered peptide ligand of autoreactive responses to the acetylcholine receptor of peripheral blood lymphocytes of patients with myasthenia gravisMolly Dayan, Zev Sthoeger, Alex Neiman, et al.
Translational Oncology|October 4, 2011
Simultaneous Inhibition of Estrogen Receptor and the HER2 Pathway in Breast Cancer: Effects of HER2 AbundanceAnna Emde, Georg Mahlknecht, Kerstin Maslak, et al.
Experimental Neurology|November 17, 2012
Magnetic resonance imaging characterization of different experimental autoimmune encephalomyelitis models and the therapeutic effect of glatiramer acetateRina Aharoni, Efrat Sasson, Tamar Blumenfeld-Katzir, et al.
Pageof 5